Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3961482 | 0.87 | EPHX2 (0.66) | EPHX2USP30 | |
| SCHEMBL12474990 | 0.87 | EPHX2 (0.66) | EPHX2USP30 | |
| SCHEMBL12474988 | 0.87 | EPHX2 (0.66) | EPHX2USP30 | |
| SCHEMBL2752048 | 0.87 | EPHX2 (0.71) | EPHX2 | |
| SCHEMBL28562966 | 0.86 | EPHX2 (0.62) | EPHX2 | |
| SCHEMBL28562963 | 0.86 | EPHX2 (0.62) | EPHX2 | |
| SCHEMBL3345439 | 0.86 | EPHX2 (0.72) | EPHX2 | |
| SCHEMBL28356482 | 0.85 | EPHX1 (0.74) | EPHX2 | |
| SCHEMBL3958181 | 0.83 | EPHX2 (0.74) | EPHX2 | |
| SCHEMBL2719754 | 0.83 | EPHX1 (0.70) | EPHX2USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090082456-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2009-03-26 | — | — | US | disclosed |
| US-20090082456-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2009-03-26 | — | — | US | disclosed |
| US-20090082456-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2009-03-26 | — | — | US | disclosed |
| WO-2009035928-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082456-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | EPHX1, EPHX2, LTA4H | EPHX2 2/4885USP30 267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.